Introduction
Minocycline is a second-generation tetracycline with improved pharmacological properties than tetracycline. It has longer half-life, better oral absorption, superior tissue penetration, change from intravenous to oral therapy, limited toxicity and most importantly can evade tetracycline-resistance mechanisms. [1] Tigecycline is the first member of glycylcycline which is derived from minocycline by the addition of a 9-tert-butyl-glycylamido side chain to the D ring at the ninth position of minocycline. This side chain aids in overcoming the ribosomal protection proteins and efflux pumps which confer resistance to other tetracyclines. [2, 3] Both the antibiotics act by inhibiting protein synthesis.
Carbapenem-resistant (CR) organisms are on the rise globally which leaves tigecycline and colistin as a last resort for treatment. With increased usage, resistance to tigecycline has increased, within a few years, tigecycline might be among the multidrug-resistant isolates from CMC hospital. Multidrug-resistant isolates are defined as those that are resistant to at least one agent in three or more classes of antimicrobials. Among ESBL producing E. coli and Klebsiella spp. percentage susceptibility to minocycline were 76 and 85, respectively. Among the CR E. coli, Klebsiella spp. and Acinetobacter spp. minocycline susceptibility were 52%, 55% and 42%, respectively. Only CR Acinetobacter spp. was included in the study and the susceptibility to minocycline is lesser than that of CR Enterobacteriaceae isolates.
Nine and six clinical isolates each of K. pneumoniae and A. baumannii were found to be susceptible to minocycline but resistant to tigecycline. Similar results have been reported by Goff and Kaye. [4] Ritchie and Garavaglia-Wilson, propose the inclusion of minocycline in the panel of antimicrobials to be tested especially for A. baumannii and not to use tetracycline as a surrogate marker. [5] Unlike tetracycline resistance which occurs mainly through increased efflux activity and ribosomal protection proteins, minocycline resistance in A. baumannii has been reported to be associated with the tet (B) efflux gene along with the plasmid-mediated ISCR-2 mobile element. Therefore, to avoid discrepant results, minocycline testing should be considered.
The literature regarding the combination testing with minocycline is limited. In 2007, Tan et al., showed 92% and 69% synergistic and bactericidal effect respectively by time-kill assay (TKA) when 13 imipenem-resistant A. baumannii were tested against a combination of minocycline with colistin. [6] Liang et al. in 2011, reported 100% synergistic activity for both minocycline with colistin and minocycline with meropenem against four extremely drug-resistant A. baumannii by TKA. [7] In 2012, Pei et al. investigated 53 CR A. baumannii against cefoperazone/sulbactam by checkerboard assay (CB) and showed 73.5% synergistic activity. [8] Recently, Zhang et al. tested 25 pan-drug resistant A. baumannii by CB showed 44% synergism for minocycline with polymyxin B. [9] There are no similar studies for Enterobacteriaceae reported.
In the recent years, there has been growing interest in minocycline for the treatment of multidrug-resistant Gram-negatives. Table 2 that an average of 59% ESBL E. coli and 51% of ESBL K. pneumoniae can be treated with minocycline. However, a higher rate of susceptibility is seen among ESBL producers in this study as mentioned in Table 1 . Approximately, 50% of the CR E. coli and K. pneumoniae can be treated with minocycline based on previous TEST studies detailed in Table 2 . Similar results were obtained for minocycline susceptibility by disc diffusion from CMC for CR E. coli and K. pneumoniae [ Table 1 ].
MIC has to be determined to consider minocycline as an alternative choice based on susceptibility profile. In addition, the lower MIC of other antibiotic can be a combination choice.
Till date, in vivo studies reported on the efficacy of minocycline for both monotherapy and combination therapy includes the following. Wood et al. and Griffith et al. in their studies using minocycline as monotherapy against wound infection and ventilator-associated pneumonia due to A. baumannii have reported 88% and 100% clinical cure, respectively. [13, 14] In in vivo studies, using minocycline both as monotherapy as well as in combination with other antimicrobial agents, Chan et al. reported 81% clinical cure for pneumonia due to A. baumannii [15] and Pogue et al. reported 69% clinical cure for bloodstream infection and pneumonia due to A. baumannii and CR K. pneumoniae. [16] Although these in vivo studies include small number of patients, they show that minocycline can be used in treatment based on susceptibility. Hence, large multicentric studies are necessary to prove the safety and efficacy of minocycline for treating multidrug-resistant infections.
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